Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Al...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

dayisthebest Sep. 16 at 9:45 PM

$AVXL if this does not get approved then patient really have no help just put them in a long term care and big pharma make more $$$. sad for patient

0 · Reply

kay91667 Sep. 16 at 9:30 PM

$AVXL CHMP meeting highlights (21–24 July 2025) — confirms 13 positive and 3 negative opinions and lists the three negative medicines. Your summary that “among the three rejected, two failed primary endpoint and the third had trial/ evidence limitations” is broadly consistent with public statements: Elevidys is a clear primary-endpoint failure; Nurzigma failed to show benefit overall with only subgroup signals; Jelrix was refused for evidence/quality gaps. I moved additional funds from my 401K into my IRA so I can start adding more tomorrow. I’m not concerned with the shorts’ short-term games—longs ultimately come out on top. Without all the short manipulation, this should already be at least $30. Good luck

0 · Reply

Ricter59 Sep. 16 at 8:50 PM

$AVXL Let’s see $10 by Friday!

0 · Reply

greedo Sep. 16 at 8:29 PM

$AVXL Don't mind me, just here to read the excuses for this terrible decline.

0 · Reply

dadojon Sep. 16 at 8:20 PM

$AVXL For your information, out of the 16 drugs listed under Section 3.1 (Opinion) in July’s CHMP agenda, 13 received a positive opinion and 3 received a negative one. This suggests that the chances of receiving a positive opinion remain strong. I’m quite confident that we will have our opinion on 14 November 2025, which means the wait is now less than two months.

2 · Reply

dayisthebest Sep. 16 at 8:03 PM

$AVXL fintel says almost 31% short crazy.

0 · Reply

prototyper Sep. 16 at 8:01 PM

$AVXL Share with me some chatGPT prompts you can use to do deep-dive research in this company. I dont have biology or science background so layman terms would be appreciated as well! Load up under 9$

3 · Reply

Blarcamesine Sep. 16 at 7:59 PM

$AVXL performance is trash!! But what happens when it gets approved and Missling does a 5 billion dollar deal . . LoL 😆

1 · Reply

TBoplano80 Sep. 16 at 7:57 PM

$AVXL Now & always

0 · Reply

dayisthebest Sep. 16 at 7:44 PM

$AVXL crazy volume so low i am amazed as so many talk this up?

0 · Reply

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 2, 2025, 7:30 AM EDT - 14 days ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Aug 26, 2025, 7:30 AM EDT - 21 days ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 20, 2025, 7:30 AM EDT - 27 days ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 12, 2025, 10:38 AM EDT - 5 weeks ago

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 5, 2025, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

May 15, 2025, 8:49 PM EDT - 4 months ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 12:21 PM EDT - 4 months ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 14, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 9:25 AM EDT - 4 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 5, 2025, 11:30 AM EDT - 5 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 6 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 14, 2025, 6:02 PM EST - 7 months ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 12, 2025, 3:13 PM EST - 7 months ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 9:59 AM EST - 7 months ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 27, 2025, 7:30 AM EST - 8 months ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 15, 2025, 7:30 AM EST - 8 months ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 8 months ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 8 months ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 9 months ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 9 months ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 9 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

Dec 24, 2024, 8:50 AM EST - 9 months ago

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 23, 2024, 10:23 AM EST - 9 months ago

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

Dec 23, 2024, 7:30 AM EST - 9 months ago

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Dec 23, 2024, 7:00 AM EST - 9 months ago

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Dec 16, 2024, 7:30 AM EST - 9 months ago

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Dec 9, 2024, 7:30 AM EST - 10 months ago

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 10 months ago

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 26, 2024, 7:30 AM EST - 10 months ago

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA

Nov 25, 2024, 7:30 AM EST - 10 months ago

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

Nov 6, 2024, 5:10 AM EST - 11 months ago

Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario

Oct 31, 2024, 4:00 AM EDT - 11 months ago

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

Oct 17, 2024, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 12:19 PM EDT - 1 year ago

Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

dayisthebest Sep. 16 at 9:45 PM

$AVXL if this does not get approved then patient really have no help just put them in a long term care and big pharma make more $$$. sad for patient

0 · Reply

kay91667 Sep. 16 at 9:30 PM

0 · Reply

Ricter59 Sep. 16 at 8:50 PM

$AVXL Let’s see $10 by Friday!

0 · Reply

greedo Sep. 16 at 8:29 PM

$AVXL Don't mind me, just here to read the excuses for this terrible decline.

0 · Reply

dadojon Sep. 16 at 8:20 PM

2 · Reply

dayisthebest Sep. 16 at 8:03 PM

$AVXL fintel says almost 31% short crazy.

0 · Reply

prototyper Sep. 16 at 8:01 PM

$AVXL Share with me some chatGPT prompts you can use to do deep-dive research in this company. I dont have biology or science background so layman terms would be appreciated as well! Load up under 9$

3 · Reply

Blarcamesine Sep. 16 at 7:59 PM

$AVXL performance is trash!! But what happens when it gets approved and Missling does a 5 billion dollar deal . . LoL 😆

1 · Reply

TBoplano80 Sep. 16 at 7:57 PM

$AVXL Now & always

0 · Reply

dayisthebest Sep. 16 at 7:44 PM

$AVXL crazy volume so low i am amazed as so many talk this up?

0 · Reply

dayisthebest Sep. 16 at 7:42 PM

$AVXL shame at $AYTR as i have sarcoidosis but with good diet well controlled . hope we don’t have a drop like that, but not sure how much we go up if approved as this stock so short controlled do we finally get a $200 squeeze????

0 · Reply

bacito Sep. 16 at 7:33 PM

$AVXL The Max Pain for triple witching Friday is $10.00.

0 · Reply

imatrader65 Sep. 16 at 7:30 PM

$AVXL apparently $9 is exactly where the tutes want it 😤.

0 · Reply

papatrick Sep. 16 at 7:19 PM

$CGTX $AVXL wrong. cgtx drug is a sigma2 antagonist and not proven out of afterwhile cherry picking

1 · Reply

Sand_Pebble Sep. 16 at 7:19 PM

$AVXL today I had a new perspective, another idea why this Anavex investment of mine is so rare. It came to me when I was reviewing the comments about the "25.4.2025" date on the CHMP Agenda from yesterday. This thread has dozens of retail frequent commentors with hundreds of years combined experience, maybe +1,000. But it appeared to me no one spoke with enough clarity & authority to give the impression they've done it before, bought a clinical stage bio & followed it step by step through the ema/chmp process? I know I haven't. In fact, almost all baby bio's I bought failed way before this point. Most clinical stage drugs fail. Getting this far has been amazing & I only need this one company to make it to be able to call it quits on investing. I've been blessed to find Blarcamesine imo.

1 · Reply

badprecog Sep. 16 at 7:06 PM

$AVXL The waiting is by far the hardest part. So glad I have you guys to chat with!

3 · Reply

Malf77 Sep. 16 at 6:57 PM

$AVXL

0 · Reply

AntonioChigurh Sep. 16 at 6:53 PM

$AVXL bought more Today. I believe something will happen next week.

1 · Reply

dadojon Sep. 16 at 6:52 PM

$AVXL After a thorough review of the CHMP agenda, it appears that medicinal products listed under section 3.1 are scheduled to receive an opinion at the conclusion of the CHMP meeting. In contrast, those categorized under section 3.2 will proceed to Clock Stop 2, implying that their evaluation process will be extended and a final decision will take longer.

3 · Reply

highnihilism Sep. 16 at 6:33 PM

IWM: Russell 2000 → $AVXL Anavex Life Sciences $TERN Terns Pharmaceuticals $FN Fabrinet $LC Lendingclub $CMRC Commerce

0 · Reply

Georgejj Sep. 16 at 6:09 PM

$AVXL Eli Lilly getting ready to partner with Anavex??! Lilly announces plans to build $5 billion manufacturing facility in Virginia https://investor.lilly.com/news-releases/news-release-details/lilly-announces-plans-build-5-billion-manufacturing-facility Good luck and GOD bless,

2 · Reply

Logic102 Sep. 16 at 5:50 PM

$CGTX Sigma 1 and Sigma 2 Agonist along with Muscarinic Agonist based treatments are the future for CNS conditions. The two names to own are Cognition and $AVXL There is skepticism but the science and data have not been refuted, at all. Buy both of these highly undervalued gems. When Blarcamesine gets a CHMP recommendation soon you will understand exactly what I have just wrote. The successes of each build on one another. Most of my eggs are in the Anavex basket with the pending approval.

2 · Reply

Market Cap	804.83M
Revenue (ttm)	0.00
Net Income (ttm)	-43.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	548,140
Avg Vol	1,067,932
Day's Range	N/A - N/A
Shares Out	85.89M
Stochastic %K	35%
Beta	0.83
Analysts	Strong Sell
Price Target	$34.33